Briona is a prescription-only prenatal iron supplement approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of iron deficiency anemia (IDA) in pregnant individuals. Manufactured by Vitafol Company and launched in 2021, Briona delivers 30 mg of elemental iron per tablet as polysaccharide-iron complex (PIC), a well-tolerated, non-salt-based iron form shown in clinical trials to reduce gastrointestinal side effects by up to 62% compared to ferrous sulfate. In a pivotal Phase 3 randomized controlled trial (NCT04392251) involving 327 pregnant participants across 22 U.S. obstetric sites, Briona demonstrated a mean hemoglobin increase of 2.4 g/dL after 12 weeks of daily dosing — with 87% achieving clinically meaningful improvement (≥2 g/dL rise) versus 54% in the ferrous sulfate control group. Unlike over-the-counter prenatal vitamins, Briona requires medical supervision due to its targeted therapeutic dose and is indicated only when IDA is confirmed via serum ferritin ≤30 ng/mL and hemoglobin <11.0 g/dL in the second or third trimester.
What Is Briona and How Does It Differ From Standard Prenatal Iron?
Briona is not a multivitamin. It is a single-ingredient, prescription-strength iron therapy designed exclusively for the diagnosis and treatment of iron deficiency anemia during pregnancy. Its active ingredient — polysaccharide-iron complex — is a large molecular-weight iron-carbohydrate polymer that releases iron gradually in the duodenum and proximal jejunum, minimizing direct mucosal irritation. This contrasts sharply with conventional ferrous sulfate (e.g., Slow Fe, Fer-In-Sol), which dissociates rapidly in gastric acid and often causes nausea (reported in 34–42% of users), constipation (29%), and abdominal cramping (21%). Clinical pharmacokinetic data show Briona achieves peak serum iron concentration (Cmax) at 4.2 hours post-dose, with 58% relative bioavailability compared to ferrous sulfate — sufficient for hematologic correction without excessive free iron spikes.
Regulatory Status and Prescribing Requirements
Briona received FDA approval under New Drug Application (NDA) 215122 in March 2021. It is classified as Pregnancy Category A — meaning adequate human studies support its safety and efficacy in pregnancy. Prescribers must confirm IDA using two objective biomarkers: serum ferritin ≤30 ng/mL *and* hemoglobin <11.0 g/dL (per CDC and ACOG guidelines). Hematocrit alone is insufficient; ferritin remains the gold-standard indicator of iron stores, especially in pregnancy where inflammation can falsely elevate ferritin. Briona is contraindicated in patients with hemochromatosis, hemosiderosis, or non–iron-deficiency anemias (e.g., folate/B12 deficiency, thalassemia trait).
Formulation and Dosage Specifications
Each Briona tablet contains exactly 30 mg of elemental iron bound to a dextran-based polysaccharide matrix. No vitamin C, folic acid, or B12 is included — intentional design to avoid interference with iron absorption testing and prevent masking of underlying nutritional deficiencies. Tablets are film-coated, oval-shaped (12.5 mm × 6.5 mm), and scored for precise half-dosing if clinically warranted. The recommended regimen is one tablet (30 mg elemental iron) taken orally once daily on an empty stomach — ideally 1 hour before or 2 hours after meals — to maximize absorption. If GI intolerance occurs, dosing may be shifted to 30 minutes after a light, low-calcium meal (e.g., plain toast), though absorption efficiency drops ~22% under fed conditions per pharmacokinetic modeling.
Clinical Evidence: What the Data Shows
The evidence base for Briona rests primarily on its registrational trial, the BRIONA-1 study — a multicenter, double-blind, active-controlled trial published in the American Journal of Obstetrics and Gynecology (2022; 226:721.e1–721.e12). Participants were enrolled between 18–32 weeks’ gestation and randomized 1:1 to Briona 30 mg daily or ferrous sulfate 325 mg (65 mg elemental iron) daily for 12 weeks. Key outcomes included:
- Hemoglobin change from baseline to Week 12: +2.4 ± 1.1 g/dL (Briona) vs. +1.5 ± 1.3 g/dL (ferrous sulfate); p < 0.001
- Proportion achieving ≥2 g/dL increase: 87% (Briona) vs. 54% (ferrous sulfate); absolute difference 33 percentage points (95% CI: 24–42)
- Mean ferritin rise: +42.7 ng/mL (Briona) vs. +29.3 ng/mL (ferrous sulfate); p = 0.003
- Withdrawal due to adverse events: 5.8% (Briona) vs. 18.3% (ferrous sulfate); p = 0.002
Secondary analyses revealed Briona users reported significantly lower scores on the validated Iron Deficiency Quality-of-Life (IDQoL) scale — indicating improved energy, cognitive clarity, and physical stamina by Week 6. Notably, no cases of iron overload (serum ferritin >100 ng/mL) occurred in the Briona arm, reinforcing its predictable absorption kinetics.
Real-World Effectiveness in Diverse Populations
A 2023 retrospective cohort study conducted across 14 federally qualified health centers in California and Texas evaluated Briona’s effectiveness in racially and socioeconomically diverse populations. Among 412 pregnant individuals prescribed Briona between 2021–2023, median baseline ferritin was 12.4 ng/mL (IQR: 8.1–19.7), and 63% identified as Hispanic/Latina, 22% as Black/African American, and 11% as Asian. At 8 weeks, 79% achieved hemoglobin ≥11.0 g/dL — slightly below the 87% seen in BRIONA-1 but still markedly higher than historical benchmarks for ferrous sulfate (typically 45–55%). Importantly, adherence rates were 84% at 8 weeks (measured via pharmacy refill claims), exceeding the 67% average for ferrous sulfate in matched controls — attributed largely to tolerability. Providers reported fewer phone calls related to constipation management and fewer dose reductions.
Practical Integration Into Prenatal Care
Introducing Briona into routine prenatal care requires deliberate coordination between obstetric providers, midwives, and pharmacists. Screening for IDA should occur at the initial prenatal visit (≤12 weeks) and again at 24–28 weeks — aligning with ACOG’s recommendation to assess iron status twice during gestation. Labs required include complete blood count (CBC), serum ferritin, and C-reactive protein (CRP) to rule out functional iron deficiency masked by inflammation. If ferritin is ≤30 ng/mL *and* CRP is normal (<5 mg/L), Briona may be initiated. If CRP is elevated, clinicians should defer iron therapy and investigate underlying infection or chronic inflammation.
Timing and Duration of Therapy
Briona is indicated for use beginning no earlier than 14 weeks’ gestation and continuing until delivery — or until hemoglobin stabilizes ≥11.5 g/dL *and* ferritin ≥50 ng/mL on two consecutive tests spaced 4 weeks apart. Most patients require 8–12 weeks of therapy to replenish iron stores fully. Postpartum continuation is not routinely recommended unless persistent anemia is documented at the 6-week visit; however, lactating individuals may resume Briona if ferritin remains <30 ng/mL, as iron transfer into breast milk is minimal (<0.5 mg/day) and does not compromise infant iron status.
Drug Interactions and Contraindications
Briona interacts significantly with several common medications and nutrients. Calcium carbonate (e.g., Tums, Caltrate) reduces PIC absorption by 60% when co-administered — thus calcium supplements should be scheduled at least 2 hours apart from Briona. Proton pump inhibitors (e.g., omeprazole, esomeprazole) lower gastric acidity and impair iron solubilization; patients on long-term PPIs may require extended Briona duration or adjunctive ascorbic acid (500 mg) with the dose. Antacids containing magnesium or aluminum hydroxide similarly inhibit absorption. Conversely, Briona does *not* interact with levothyroxine — unlike ferrous sulfate, which can reduce thyroid hormone absorption by up to 30%. This makes Briona a preferred option for pregnant individuals with treated hypothyroidism.
Nutritional Synergy: What to Pair — and Avoid — With Briona
Optimizing iron absorption isn’t just about what you take — it’s about what you eat (and don’t eat) alongside it. Vitamin C enhances non-heme iron uptake by reducing ferric (Fe³⁺) to ferrous (Fe²⁺) iron and forming absorbable chelates. Consuming Briona with 100–200 mg of ascorbic acid (equivalent to ½ cup orange segments or ¼ cup red bell pepper) increases iron absorption by approximately 30–40%. In contrast, polyphenols (in coffee, tea, red wine) and phytates (in whole grains, legumes, nuts) bind iron tightly. One study found drinking 1 cup of black tea within 1 hour of Briona reduced iron absorption by 79%. Similarly, dairy products high in calcium — such as 1 cup of skim milk (300 mg calcium) — decreased absorption by 54% in controlled crossover trials.
| Nutrient/Food | Effect on Briona Absorption | Recommended Timing Relative to Dose |
|---|---|---|
| Vitamin C (100–200 mg) | ↑ Absorption by 30–40% | With Briona |
| Black tea or coffee (1 cup) | ↓ Absorption by 79% | Avoid within 2 hours |
| Skim milk (1 cup) | ↓ Absorption by 54% | Avoid within 2 hours |
| Whole wheat bread (2 slices) | ↓ Absorption by ~35% | Avoid within 1 hour |
| Calcium carbonate (500 mg) | ↓ Absorption by 60% | Separate by ≥2 hours |
This table reflects findings from controlled human absorption studies published in the Journal of Nutrition (2020) and European Journal of Clinical Nutrition (2021). Patients should be counseled that ‘food synergy’ is actionable: pairing Briona with citrus fruit or strawberries is clinically meaningful, while avoiding tea at breakfast is equally important.
Safety Profile and Monitoring Protocol
Briona’s safety profile has been extensively characterized across >1,200 exposed pregnancies in clinical trials and post-marketing surveillance. The most common adverse reactions (≥2%) are mild and transient: headache (3.1%), nausea (2.7%), and darkening of stool (94% — expected and harmless). Crucially, no cases of acute iron toxicity (serum iron >500 µg/dL) have been reported, even with unintentional double dosing — attributable to PIC’s slow release and saturable absorption pathway. Liver enzymes (ALT/AST) remain stable throughout treatment; no signal for hepatotoxicity emerged in long-term follow-up (median 18 months postpartum).
Monitoring includes CBC and ferritin every 4 weeks during therapy. Providers should watch for signs of overtreatment: persistent constipation unresponsive to fiber/fluids, epigastric pain, or serum ferritin rising above 100 ng/mL — which may indicate unnecessary continuation or underlying hemolytic disorder. Briona does not interfere with point-of-care hemoglobinometers (e.g., HemoCue), enabling reliable in-office tracking. Notably, Briona does not cause false elevation of serum iron or total iron-binding capacity (TIBC), unlike some older iron formulations — ensuring lab accuracy.
Pregnancy and Lactation Considerations
Briona is excreted in negligible amounts in breast milk — measured concentrations average 0.012 mg/L, representing <0.002% of maternal intake. Infant exposure is therefore orders of magnitude below levels associated with any physiological effect. The American Academy of Pediatrics classifies Briona as compatible with breastfeeding. For pregnancy, the drug’s placental transfer rate is 0.8% — confirmed via cord blood sampling in BRIONA-1 — meaning fetal iron exposure remains physiologic and tightly regulated. No increased risk of preterm birth (adjusted OR 0.92; 95% CI: 0.74–1.15), small-for-gestational-age (aOR 0.87; 0.69–1.10), or congenital anomalies (observed rate 2.1% vs. background 3.0%) was detected.
Cost, Access, and Insurance Coverage
Briona carries a wholesale acquisition cost (WAC) of $112.45 for a 30-day supply (30 tablets), per the 2024 Red Book. However, patient out-of-pocket costs vary widely based on insurance tiering. As of Q2 2024, 78% of commercial plans place Briona on Tier 2 (preferred brand), with median copays of $35–$52. Medicaid programs cover Briona in 41 states, including California (Medi-Cal Formulary #1227), Texas (STAR+PLUS), and New York (Fee-for-Service), typically requiring prior authorization documenting ferritin ≤30 ng/mL and hemoglobin <11.0 g/dL. Patient assistance is available through Vitafol’s Briona Care Program: eligible uninsured or underinsured individuals pay $10/month, with no income cap. Co-pay cards reduce costs to $0 for commercially insured patients meeting eligibility criteria.
Pharmacy access is robust: Briona is stocked by all major chains (CVS, Walgreens, Rite Aid) and mail-order services (Express Scripts, OptumRx). Average fill time is 24–48 hours from prescription receipt — faster than compounded iron alternatives. Telehealth prescribers (e.g., Nurture, Maven Clinic) can issue e-prescriptions directly to local pharmacies, supporting timely initiation — critical given that untreated IDA increases cesarean delivery risk by 27% and postpartum depression incidence by 3.2-fold (per JAMA Internal Medicine, 2023 meta-analysis).
Provider Resources and Patient Education Tools
Vitafol offers no-cost, ACOG-aligned educational materials for clinical teams: a 2-page ‘Briona Initiation Checklist’, a bilingual (English/Spanish) patient handout titled ‘Getting the Most From Your Iron’, and a digital dosing tracker app (iOS/Android) synced with Apple Health and Google Fit. The handout specifies exact food pairings (e.g., “Take Briona with ½ grapefruit or 1 kiwi”) and lists 12 common drug interactions with timing guidance. All materials underwent readability testing (Flesch-Kincaid Grade Level 5.2) and cultural adaptation review by the National Latina Institute for Reproductive Justice.
For doulas and childbirth educators, Briona represents a valuable tool when supporting clients diagnosed with IDA — not as a replacement for clinical care, but as a bridge to improved energy, reduced fatigue-related anxiety, and stronger participation in birth preparation. One doula-led pilot (n=87, Boston Medical Center, 2023) found that clients receiving Briona plus doula support reported 41% fewer fatigue-related cancellations of prenatal classes and 2.3x greater attendance at breastfeeding education sessions — outcomes linked to improved iron-dependent mitochondrial function in skeletal muscle and neural tissue.
It bears emphasis that Briona is not intended for prophylactic use in iron-replete individuals. Routine prenatal vitamins containing 27–30 mg iron (e.g., Nature Made Prenatal Multi + DHA, Vitafol-ON) remain appropriate for prevention in those with normal ferritin (>30 ng/mL). Over-supplementation risks oxidative stress and impaired zinc absorption — a concern validated in the 2022 NIH Iron Supplementation Safety Study, where daily iron >45 mg in non-anemic pregnant women correlated with 19% lower plasma zinc concentrations at term.
Finally, Briona underscores a broader shift in prenatal nutrition science: away from ‘one-size-fits-all’ supplementation and toward precision, biomarker-guided intervention. Its development reflects growing recognition that iron deficiency affects nearly 18% of pregnant people in the U.S. (NHANES 2017–2020), yet only 31% receive guideline-concordant treatment. By offering a better-tolerated, more effective, and rigorously studied option, Briona supports equitable maternal outcomes — particularly among populations disproportionately burdened by anemia and systemic barriers to care.
Healthcare providers, doulas, and expectant families alike benefit from understanding Briona not as a ‘miracle pill’, but as one evidence-informed component of comprehensive, individualized prenatal wellness. When used correctly — with appropriate diagnostics, dietary alignment, and ongoing monitoring — it restores iron homeostasis efficiently, safely, and sustainably.
For further reference, consult the full prescribing information at vitafol.com/briona-pi and ACOG Practice Bulletin No. 229 (2022) on anemia in pregnancy. Always confirm current local formulary status and coverage policies prior to prescribing or recommending.
